Cardiol Therapeutics (CRDL) Cash from Investing Activities (2020 - 2026)
Cardiol Therapeutics (CRDL) posted Cash from Investing Activities of -$34699.3 for Q1 2026, down 1467.01% on a QoQ basis from -$2214.4 in Q4 2025, and down 317.03% year-over-year from $15987.9 in Q1 2025.
Cardiol Therapeutics (CRDL) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Cardiol Therapeutics' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$34699.3 for Q1 2026.
- Quarterly Cash from Investing Activities fell 317.03% year-over-year to -$34699.3 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$43753.7 (down 105.63% YoY) and the FY2025 annual result came in at -$17557.1, down 15.2% from the prior year.
- Cash from Investing Activities was -$34699.3 for Q1 2026 at Cardiol Therapeutics, down from -$2214.4 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$1669.1 in Q2 2022 and bottomed at -$35236.5 in Q4 2022.
- A 5-year average of -$10082.5 and a median of -$4647.1 in 2025 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2024 — Cash from Investing Activities soared 92.14% — and 2026, when it plunged 317.03%.
- Cardiol Therapeutics' Cash from Investing Activities stood at -$35236.5 in 2022, then jumped by 77.68% to -$7863.9 in 2023, then jumped by 43.94% to -$4408.9 in 2024, then jumped by 49.78% to -$2214.4 in 2025, then plunged by 1467.01% to -$34699.3 in 2026.
- Business Quant data shows CRDL's Cash from Investing Activities at -$34699.3 in Q1 2026, -$2214.4 in Q4 2025, and -$2193.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.68 Bn | 30.74 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.63 Bn | 23.57 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 23.16 Bn | 21.01 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.34 Bn | 18.54 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Cardiol Therapeutics | 129.15 Mn | 129.15 Mn | - | -34,699.25 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34,699.25 |
| Mar 31, 2026 | -34,699.25 |
| Dec 31, 2025 | -2,214.36 |
| Dec 31, 2025 | -2,214.36 |
| Sep 30, 2025 | -2,192.98 |
| Sep 30, 2025 | -2,192.98 |
| Jun 30, 2025 | -4,647.11 |
| Jun 30, 2025 | -4,647.11 |
| Mar 31, 2025 | -8,320.49 |
| Mar 31, 2025 | -8,320.49 |
| Dec 31, 2024 | -4,408.91 |
| Dec 31, 2024 | -4,408.91 |
| Sep 30, 2024 | -5,769.86 |
| Sep 30, 2024 | -5,769.86 |
| Jun 30, 2024 | -2,778.33 |
| Jun 30, 2024 | -2,778.33 |
| Mar 31, 2024 | -2,567.71 |
| Mar 31, 2024 | -2,567.71 |
| Dec 31, 2023 | -7,863.94 |
| Dec 31, 2023 | -7,863.94 |